0001898521-25-000003.txt : 20251223 0001898521-25-000003.hdr.sgml : 20251223 20251223182014 ACCESSION NUMBER: 0001898521-25-000003 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20251222 FILED AS OF DATE: 20251223 DATE AS OF CHANGE: 20251223 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Rochlin Kate CENTRAL INDEX KEY: 0001898521 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39692 FILM NUMBER: 251602038 MAIL ADDRESS: STREET 1: IN8BIO, INC. STREET 2: EMPIRE STATE BUILDING, SUITE 5330 CITY: NEW YORK STATE: NY ZIP: 10118 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: IN8BIO, INC. CENTRAL INDEX KEY: 0001740279 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 825462585 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: EMPIRE STATE BUILDING STREET 2: 350 5TH AVENUE, SUITE 5330 CITY: NEW YORK STATE: NY ZIP: 10118 BUSINESS PHONE: (646) 600-6438 MAIL ADDRESS: STREET 1: EMPIRE STATE BUILDING STREET 2: 350 5TH AVENUE, SUITE 5330 CITY: NEW YORK STATE: NY ZIP: 10118 FORMER COMPANY: FORMER CONFORMED NAME: Incysus Therapeutics, Inc. DATE OF NAME CHANGE: 20180510 4 1 form4-12232025_061210.xml X0508 4 2025-12-22 0001740279 IN8BIO, INC. INAB 0001898521 Rochlin Kate C/O IN8BIO, INC. 350 5TH AVE. SUITE 5330 NEW YORK NY 10118 false true false false Chief Operating Officer 0 Common Stock 2025-12-22 4 A 0 7247 1.38 A 9085 D Effective June 3, 2025, the Issuer effected a 1-for-30 reverse stock split of the Issuer's common stock. The number of securities reported herein have been adjusted to reflect the reverse stock split. /s/ William Ho, Attorney-in-Fact 2025-12-23